Towards standardizing basophil identification by flow cytometry., PMID:36938328
Can Immune Therapy Cure Acute Myeloid Leukemia?, PMID:36949279
Blastic Plasmacytoid Dendritic Cell Neoplasm., PMID:37156483
Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies., PMID:37452102
CSL362 potently and specifically depletes pDCs invitro and ablates SLE-immune complex-induced IFN responses., PMID:37456846
The Contribution of Multiplexing Single Cell RNA Sequencing in Acute Myeloid Leukemia., PMID:37489448
Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid-Antibody-Drug Conjugates., PMID:37493255
Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia., PMID:37524506
Twenty-four-color full spectrum flow cytometry panel for minimal residual disease detection in acute myeloid leukemia., PMID:37533738
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia., PMID:37647601
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia., PMID:37648862
Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies., PMID:37673048
Update on immune-based therapy strategies targeting cancer stem cells., PMID:37698048
15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges., PMID:37706583
Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations., PMID:37729719
Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy., PMID:37773046
Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas., PMID:37998391
Plasmacytoid Dendritic Cells, the Expression of the Stimulator of Interferon Genes Protein (STING) and a Possible Role of Th17 Immune Response in Cervical Lesions Mediated by Human Papillomavirus., PMID:38031606
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia., PMID:38075241
Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile., PMID:38266153
Case report: Kikuchi-Fujimoto disease: unveiling a case of recurrent fever and enlarged cervical lymph nodes in a young female patient with a literature review of the immune mechanism., PMID:38313434
Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123., PMID:38338733
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study., PMID:38423051
Immunophenotypic characterization of leukemic stem cells in acute myeloid leukemia using single tube 10-colour panel by multiparametric flow cytometry: Deciphering the spectrum, complexity and immunophenotypic heterogeneity., PMID:38456256
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123., PMID:38492495
Erythema Multiforme-Like Fixed Drug Eruption During Azathioprine and Hydroxychloroquine Treatment for Systemic Lupus Erythematosus Mimicking Rowell Syndrome: A Rare and Challenging Clinical Scenario., PMID:38494929
Identification of Specific Cell Surface Markers on Immune Cells of Squirrel Monkeys (Saimiri sciureus)., PMID:38566886
Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study., PMID:38629176
[Preparation of a dual-specific antibody targeting human CD123 and exploration of its anti-acute myeloid leukemia effects]., PMID:38716593
TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates., PMID:38768424
Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells., PMID:38819256
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia., PMID:38904305
Olverembatinib combined with inotuzumab ozogamicin in relapsed refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report., PMID:39029009
Good manufacturing practice-grade generation of CD19 and CD123-specific CAR-T cells using piggyBac transposon and allogeneic feeder cells in patients diagnosed with B-cell non-Hodgkin lymphoma and acute myeloid leukemia., PMID:39192973
Current status and research directions in acute myeloid leukemia., PMID:39300079
Advancements in leukemia management: Bridging diagnosis, prognosis and nanotechnology (Review)., PMID:39364739
Hairy cell leukemia (HCL) and HCL-like disorders: present, emergent treatment options and future directions., PMID:39535173
Acute myeloid leukemia management and research in 2025., PMID:39656142
The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia., PMID:39830370
Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies., PMID:39864030
A novel label-free method to determine equilibrium dissociation constants of antibodies binding to cell surface proteins., PMID:39870691
Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality., PMID:39915004
Clinical, Histopathological, and Therapeutic Features in Lupus Erythematosus Tumidus: A Retrospective Study., PMID:39947587
A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): monoclonal antibodies (mAbs) and beyond., PMID:40069930
Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632)., PMID:40119158
Evaluation of Dendritic Cell Subpopulations Frequency in COVID-19 Patients and their Correlation with Disease Severity., PMID:40130356
Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm., PMID:40141368
Combining CD64 and CD123 Biomarkers for Sepsis Early Diagnosis and Severity Assessment via PD-L1 Antibody Affinity Microfluidic (PAAM) Chip in Trace Clinical Samples., PMID:40177943
Establishment of a novel human basophil cell line for functional analysis and in vitro allergy testing., PMID:40187962
Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions., PMID:40429716
For research use only. Not for human or drug use.
